BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Recursion Pharmaceuticals Stock Dives Amid Analyst Cut and Insider Sales
Recursion Pharmaceuticals Stock Dives Amid Analyst Cut and Insider Sales
21
1
BTCCSquare news:
Recursion Pharmaceuticals (RXRX) shares plummeted over 17% this week following a double blow from Wall Street and corporate insiders. Morgan Stanley analyst Sean Laaman slashed his price target by $0.20 to $4.80 while maintaining a neutral rating, signaling tempered expectations for the clinical-stage biotech firm.
Regulatory filings revealed substantial stock sales by key executives, compounding investor concerns. CEO Christopher Gibson and Chief R&D Officer Najit Khan each disposed of approximately 40,000 shares, with disclosures indicating most sales were required to satisfy tax obligations. Such concentrated insider selling often rattles market confidence, particularly when paired with downward analyst revisions.
By:
